Statistical analysis Chi2 test was used to compare proportions and Mann Whitney U tests to compare median values between groups. Survival times were estimated using the Kaplan-Meier method and the differences were tested with the log-rank test. Analysis was performed with Statistica (StatSoft, Inc. (2004). STATISTICA (data analysis software system), version 6. http://​www.​statsoft.​com). Results Patients with BCLC stage A 40 patients were classified to BCLC stage A. Treatment modalities in this group were: long-acting octreotide [Sandostatin LAR] (n = 11 [27.5%]), TACE (n = 5 [12.5%]), multimodal therapy as defined above

(n = 7 [17.5%]) and selleckchem palliative care only (17 [42.5%]). Median Survival (Figure 1) Figure 1 Patients with hepatocellular carcinoma and BCLC stage A. Median survival rates in long-acting octreotide [Sandostatin selleck kinase inhibitor LAR], TACE, multimodal therapy and palliative care were 31.4, 37.3, 40.2 and 15.1 months respectively. Survival rates of patients with active treatment did not differ significantly. Overall median survival was 18.4 months. Median survival rates in long-acting octreotide [Sandostatin LAR], TACE, multimodal therapy and palliative care were 31.4, 37.3, 40.2 and 15.1 months respectively (Table 2). Although survival rates of patients with “”active”" treatment (long-acting octreotide [Sandostatin LAR], TACE or multimodal DNA Damage inhibitor therapy) were more than twice as long as of

patients who received only palliative care this difference was not significant. Survival rates of patients with various active treatment modalities Epothilone B (EPO906, Patupilone) did not differ significantly. Table 2 Patient survival according to BCLC stage and treatment     BCLC A BCLC B     number median survival (months) log rank test number median survival (months) log rank test number treatment modalities   40     55       Sandostatin LAR 11 31.4 P = 0.35038 14 22.4 P = 0.00003   TACE 5 37.3   9 22.0     multimodal therapy 7 40.2   10 35.5    

palliative care 17 15.1   22 2.9   The 1 year survival rate in the long-acting octreotide [Sandostatin LAR] group was 64% and in patients who received multimodal therapy, TACE, and palliative care 86%, 80% and 53%, respectively. The 2 year survival rate in the long-acting octreotide [Sandostatin LAR] group was 55% and in patients who received multimodal therapy, TACE, and palliative care 82%, 60% and 29%, respectively. Patients with BCLC Stage B 55 patients were classified as BCLC stage B. These patients received long-acting octreotide [Sandostatin LAR] (n = 14 [25.4%]), TACE (n = 9 [16.4%]), multimodal therapy as defined above (n = 10 [18.2%]) and palliative care (n = 22 [40.0%]), respectively. Median Survival (Figure 2) Figure 2 Patients with hepatocellular carcinoma and BCLC stage B. Median survival rates in long-acting octreotide [Sandostatin LAR], TACE, multimodal therapy and palliative care were 22.4, 22.0, 35.5 and 2.